BioLife Solutions, Inc. (NASDAQ:BLFS) Director Andrew G. Hinson sold 2,500 shares of BioLife Solutions stock in a transaction dated Monday, May 17th. The stock was sold at an average price of $29.06, for a total value of $72,650.00. Following the transaction, the director now directly owns 9,461 shares in the company, valued at $274,936.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NASDAQ:BLFS traded up $0.82 on Monday, hitting $30.56. 256,257 shares of the company’s stock traded hands, compared to its average volume of 300,547. BioLife Solutions, Inc. has a 1 year low of $14.43 and a 1 year high of $47.97. The firm has a 50-day moving average price of $33.72 and a 200-day moving average price of $37.30. The company has a market cap of $1.03 billion, a PE ratio of -41.86, a price-to-earnings-growth ratio of 50.41 and a beta of 1.55.
BioLife Solutions (NASDAQ:BLFS) last released its earnings results on Wednesday, May 12th. The medical equipment provider reported ($0.03) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.01) by ($0.02). BioLife Solutions had a net margin of 12.67% and a return on equity of 0.53%. Analysts predict that BioLife Solutions, Inc. will post 0.01 earnings per share for the current fiscal year.
Several institutional investors have recently made changes to their positions in BLFS. Strs Ohio acquired a new stake in shares of BioLife Solutions during the 4th quarter valued at about $31,000. US Bancorp DE lifted its holdings in shares of BioLife Solutions by 6,204.4% during the 1st quarter. US Bancorp DE now owns 2,837 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 2,792 shares during the last quarter. Parallel Advisors LLC acquired a new stake in shares of BioLife Solutions during the 4th quarter valued at about $113,000. Citigroup Inc. lifted its holdings in shares of BioLife Solutions by 265.7% during the 4th quarter. Citigroup Inc. now owns 3,156 shares of the medical equipment provider’s stock valued at $126,000 after buying an additional 2,293 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of BioLife Solutions during the 4th quarter valued at about $194,000. Institutional investors and hedge funds own 67.66% of the company’s stock.
BioLife Solutions Company Profile
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.